ISG15 targets glycosylated PD-L1 and promotes its degradation to enhance antitumor immune effects in lung adenocarcinoma

Tongyuan Qu,Wenshuai Zhang,Chenhui Yan,Danyang Ren,Yalei Wang,Yuhong Guo,Qianru Guo,Jinpeng Wang,Liren Liu,Lei Han,Lingmei Li,Qiujuan Huang,Lu Cao,Zhaoxiang Ye,Bin Zhang,Qiang Zhao,Wenfeng Cao
DOI: https://doi.org/10.1186/s12967-023-04135-1
IF: 8.44
2023-05-23
Journal of Translational Medicine
Abstract:Immunocheckpoint inhibitors (ICIs) have been widely used in the clinical treatment of lung cancer. Although clinical studies and trials have shown that patients can benefit significantly after PD-1/PD-L1 blocking therapy, less than 20% of patients can benefit from ICIs therapy due to tumor heterogeneity and the complexity of immune microenvironment. Several recent studies have explored the immunosuppression of PD-L1 expression and activity by post-translational regulation. Our published articles demonstrate that ISG15 inhibits lung adenocarcinoma progression. Whether ISG15 can enhance the efficacy of ICIs by modulating PD-L1 remains unknown.
medicine, research & experimental
What problem does this paper attempt to address?